🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› EU
Clinical trial register · European Union · CTIS

Recently authorised EU trials

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12479 total CTIS records — a stated recency window, not the full historical archive. Synced 24 Sep 2026, 03:17 UTC
2500
Shown in this register
most recently authorised
12,479
Total on CTIS
full historical archive
743
Phase III
within the shown window
Top member states
Spain 1015 France 884 Germany 862 Italy 739 Poland 582 Netherlands 531
Narrow the register
Phase
Phase I 555 Phase I/II 212 Phase II 730 Phase III 743 Phase IV 260
Lead sponsor
AstraZeneca AB 63 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 44 Novo Nordisk A/S 43
Member state
Spain 1015 France 884 Germany 862 Italy 739 Poland 582 Netherlands 531 Belgium 431 Czechia 331
All 28 states

Trials in this register

2500 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase II
Up-titration of sulfonylurea (SU) in individuals with HNF1A- and HNF4A-MODY – A Steno MODERN-MODY project (MM-SUUP)
2025-524679-22-00Maturity-onset diabetes of the young type 3 (HNF1A-MODY), M…
Steno Diabetes Center Copenhagen
Hormonal diseases
Denmark
04/03/2026
Phase IV
Intrathecal drug delivery systems versus comprehensive medical management for severe cancer pain: a randomized controlled trial
2025-522381-68-00Severe refractory cancer pain
Vrije Universiteit Brussel
Anesthesia and Analgesia
Belgium
04/03/2026
Phase I
Randomized, open-label, laboratory-blinded, balanced, single dose, 3-treatment, 6-sequence, 3-period crossover comparative bioavailability study comparing Finerenone, 20 mg, film-coated tablets (Prototype 1, Prototype 2) and Kerendia, 20 mg, film-coated tablets under fasting conditions in healthy participants.
2026-525256-29-00Comparative bioavailability study under fasting conditions
ZAKLADY FARMACEUTYCZNE POLPHARMA S.A.
Cardiovascular Diseases
Czechia
04/03/2026
Phase III
A Phase III, multisite, randomized, double-blind trial of BNT327 in combination with chemotherapy versus placebo with chemotherapy in patients with previously untreated locally recurrent inoperable or metastatic TNBC determined ineligible for PD(L)1 therapy based on PD-L1 negative disease
2025-521884-12-00First line triple-negative breast cancer (TNBC)
BioNTech SE
Neoplasms
Czechia, Poland, Italy, France, Belgium, Netherlands, Germany, Spain
04/03/2026
Phase I
Crossover study to investigate the safety and tolerability as well as the blood levels after three single doses of Tacrolimus, of which 2 are administered via the cheek mucosa and 1 dose via the mouth (oral).
2025-525076-29-00Phase I study in healthy male volunteers. Intended indicati…
Nucleus Medical GmbH
Immune system processes
Germany
04/03/2026
Phase II
A Phase 2, Multi-center, Randomized, Dose-Ranging, Placebo-Controlled, Double-blind Study of the Relaxin Agonist R2R01 in Patients at High Risk for Cardiac Surgery Associated - Acute Kidney Injury.
2025-523037-25-00Patients at high risk for Cardiac Surgery Associated – Acut…
River 2 Renal Corp.
Pathological Conditions, Signs and Symptoms
Italy, Germany
04/03/2026
Phase I/II
Protocol Title: KEYMAKER-U01 Substudy 01F: A Phase 1b/2 Umbrella Study With Rolling Arms of Investigational Agents for Previously Treated of Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations
2024-512248-47-00Non-small Cell Lung Cancer (NSCLC)
Merck Sharp & Dohme LLC
Neoplasms
Italy, Germany, Greece, Poland, Hungary, Spain
04/03/2026
Phase IV
A Pragmatic Randomized Trial to Evaluate the Effect of Recombinant Herpes Zoster Vaccine on Major Adverse Cardiovascular Events and Dementia in Adults Aged 65 Years or Above
2025-524944-37-00Herpes Zoster
Gentofte Hospital, GlaxoSmithKline Biologicals
Skin and Connective Tissue Diseases
Denmark
04/03/2026
Phase II
Pilot study of the efficacy of nicotinamide (vitamin B3) in Leber's hereditary optic neuropathy - NICOLHON
2025-524343-13-00Leber's Hereditary Optic Neuropathy
Centre Hospitalier Universitaire D'Angers
Eye Diseases
France
03/03/2026
Phase I
Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors
2025-523232-39-00Advanced Solid Tumors
Merck Healthcare KGaA
Neoplasms
Spain
03/03/2026
Phase III
A randomized, double-blind, placebo-controlled Phase III study to evaluate the efficacy and safety of remibrutinib in patients with secondary progressive multiple sclerosis
2025-521546-23-00Secondary progressive multiple sclerosis
Novartis Pharma AG
Nervous System Diseases
Denmark, Slovenia, Netherlands, Portugal, Ireland, Sweden, Croatia, Greece, Germany, Latvia, Czechia, Spain, Romania, Belgium, Austria, Lithuania, Slovakia, Poland, Estonia, Bulgaria, France, Italy, Hungary, Finland, Norway
03/03/2026
Phase IV
Impact of Early Thyroid Hormone Replacement on Kidney Function and Health-Related Quality of Life in Patients at Risk of Postoperative Hypothyroidism after Hemithyroidectomy: A Randomised Controlled Trial
2025-524175-23-00Hypothyroidism, Incident Kidney Dysfunction, Chronic Kidney…
Region Midtjylland
Otorhinolaryngologic Diseases
Denmark
03/03/2026
Phase III
A double blind, randomized, placebo-controlled exploratory trial to investigate the efficacy and safety of nerandomilast over 24 months when administered in individuals with interstitial lung abnormalities and a family history of pulmonary fibrosis to reduce the risk of worsening (DROP-FPF)
2025-522383-33-00Pulmonary fibrosis, Interstitial lung diseases, Familial pu…
Boehringer Ingelheim International GmbH
Respiratory Tract Diseases
Belgium, Spain, Netherlands, Italy, Germany, France
03/03/2026
Phase III
A prospective, open-label, single-arm, multicenter study evaluating the efficacy of Xanomeline/Trospium (XT) on cognitive impairment after 24 and 52 weeks of treatment in adult participants with schizophrenia.
2025-523060-20-00Schizophrenia
European Group for Research in Schizophrenia Stichting
Mental Disorders
Denmark, Belgium, Italy, Netherlands, Hungary, Czechia, Austria, Spain, Germany
03/03/2026
Phase I/II
A Modular Phase I/II Open-label Dose Escalation and Dose Expansion Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of AZD9793, a T cell-engaging Antibody Targeting Glypican-3 (GPC3) in Adult Participants with Advanced or Metastatic Solid Tumours (RHEA-1)
2024-516698-56-00Hepatocellular Carcinoma
AstraZeneca AB
Neoplasms
Spain
03/03/2026
Phase I
C6001001 - A Study to Learn about the Study Medicine PF-08052667 in People with Bladder Cancer.
2025-521756-39-00Non-muscle invasive bladder cancer (NMIBC)
Pfizer Inc.
Neoplasms
France, Spain
02/03/2026
Phase II
A Phase 2 Study to Assess ADX-038 in Participants With Complement-Mediated Kidney Disease
2025-521752-26-00Complement-Mediated Kidney Disease
Adarx Pharmaceuticals Inc.
Male Urogenital Diseases
Spain, Italy
02/03/2026
Phase II
A phase II study of ficerafusp alfa (BCA 101) in combination with nivolumab in platinum refractory head and neck squamous cell carcinoma patients who progressed within 6 months after multimodal treatment for locally advanced disease ( BICARA)
2025-521437-88-00head and neck squamous cell carcinoma
Groupe Oncologie Radiotherapie Tete Cou
Neoplasms
France
02/03/2026
Phase II
Randomised EValuation of Therapies for microvAscuLar Injury in STEACS – REVITALISE Study
2025-522060-32-00STEMI (ST elevated Myocardial Infarction)
CorFlow Therapeutics AG, CorFlow Therapeutics AG
Cardiovascular Diseases
Netherlands, Spain, France
02/03/2026
Phase II
Fibroblast markers to tackle fibrosis in immune-mediated inflammatory diseases
2025-522834-30-01Systemic sclerosis (SSc), Idiopathic pulmonary fibrosis (IP…
Amsterdam UMC Stichting
Skin and Connective Tissue Diseases
Netherlands
02/03/2026
Phase II
COMPARISON OF ZINC ACETATE DOSE REGIMENS (GALZIN VS. ET-700) FOR THE TREATMENT OF WILSON DISEASE: A PHARMACODYNAMIC 64CUCL2 PET/CT STUDY IN HEALTHY PARTICIPANTS
2025-523372-24-00Wilson's Disease
Region Midtjylland
Nutritional and Metabolic Diseases
Denmark
02/03/2026
Phase I
A clinical trial of MK-6916 in healthy participants (MK-6916-010)
2025-524570-41-00Acute and Chronic pain
Merck Sharp & Dohme LLC
Nervous System Diseases
Belgium
02/03/2026
Phase III
Prospective Multicenter Randomized Non-Inferiority Study Comparing 7 Days Versus 14 Days of Antibiotic Treatment for Graft Pyelonephritis in Kidney Transplant Recipients (KTI)
2025-523120-53-00Graft pyelonephritis in kidney transplant recipients
Bellvitge University Hospital, Fundacio Institut D'Investigacio Biomedica De Bellvitge IDIBELL
Bacterial Infections and Mycoses
Spain
02/03/2026
Phase II
An open label extension study to evaluate the long-term safety and efficacy of subcutaneous lunsekimig in adult participants with asthma who participated in study DRI16762 or ACT18301
2025-522896-27-00Asthma
Sanofi-Aventis Recherche & Developpement
Respiratory Tract Diseases
Poland, Italy, Belgium, Sweden, Hungary, France, Germany, Spain, Denmark
02/03/2026
Phase II
A randomized, double-blind, placebo-controlled, Phase 2, dose-finding study to investigate the efficacy and safety of SAR445399 in participants with moderate to severe hidradenitis suppurativa
2025-522695-83-00Hidradenitis suppurativa
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Hungary, Spain, France, Belgium, Sweden, Germany, Italy
02/03/2026
Phase II
Efficacy and safety of Ursodeoxycholic Acid as a new therapy for the treatment of hepatorenal polycystic diseases, genetic study and determination of prognostic biomarkers.
2024-513644-28-00Hepatorenal polycystic diseases
Asociacion Instituto Biogipuzkoa
Digestive System Diseases
Spain
02/03/2026
Phase I
A Phase 1 study to evaluate the effect of BV100 on the pharmacokinetics of polymyxin B in healthy volunteers
2025-521020-30-00Healthy volunteer trial. Intended indication: treatment of …
Bioversys S.A.S.
Respiratory Tract Diseases
Austria
01/03/2026
Phase III
Effect of nepafenac/dexamethasone fixed dose combination vs. its individual components (nepafenac and dexamethasone monotherapies) on postoperative inflammation after cataract surgery: a randomized, multicentre, blinded-assessor, parallel-group clinical study – NE.DE.F. STUDY
2025-523367-38-00Postoperative inflammation after cataract surgery
Medivis S.r.l.
Eye Diseases
Italy
27/02/2026
Phase II
C5041018 - A Phase 2 Open-Label, Single Arm Study to Evaluate the Efficacy, Pharmacokinetics, and Safety of Etrasimod in Pediatric Participants with Moderately to Severely Active Ulcerative Colitis
2025-523100-77-00Ulcerative Colitis
Pfizer Inc.
Digestive System Diseases
Finland, Poland, France, Germany, Italy, Slovakia
27/02/2026
Phase III
TIC-TAC-SAM « Comparison of two strategies of etoposide initiation in severe sporadic hemophagocytic lymphohistiocytosis in intensive care: a randomized trial »
2024-511807-41-01Hemophagocytic lymphohistiocytosis (HLH)
Assistance Publique Hopitaux De Paris
Pathological Conditions, Signs and Symptoms
France
27/02/2026
Phase II
A phase 2, single arm, open label, study on the safety and feasibility of Liver Isolated Oxaliplatin (LIOX) delivered via arterial access device for treatment of liver metastasis in colorectal cancer patients
2025-523261-25-00colorectal cancer
UZ Leuven
Neoplasms
Belgium
27/02/2026
Phase I/II
A Modular, Open Label, Dose Finding Phase 1/2 Clinical Trial in Patients with Solid Tumours to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of PTT-4256 (RAISIC-1: Relief of Acidic Immune Suppression In Cancer)
2025-522944-41-00Solid Tumours
Pathios Therapeutics Limited
Not possible to specify
France, Spain
27/02/2026
Phase III
HighLiGHts - A Pivotal, Parallel-Arm, Phase 3, Open-Label, Active-controlled, Global, Multicenter, Randomized Basket Trial Investigating the Efficacy and Safety of Once-weekly Lonapegsomatropin Compared to Daily Somatropin in Prepubertal Children and Adolescents with Growth Failure or Short Stature due to Growth Hormone Sufficient Disorders – Turner Syndrome, SHOX Deficiency, Small for Gestational Age, and Idiopathic Short Stature
2025-523079-44-00Turner Syndrome (TS), idiopathic short stature (ISS), short…
Ascendis Pharma Endocrinology Division A/S
Musculoskeletal Diseases
Germany, Spain, Italy, France, Romania
27/02/2026
Phase II
POSITRON - PsilOcybin with pSychologIcal supporT foR cOcaiNe: a randomised controlled pilot feasibility trial of psilocybin with psychological support for cocaine use disorder
2024-515147-32-02Cocaine addiction
Trinity College Dublin
Mental Disorders
Ireland
27/02/2026
Phase II
A Phase 2a, Open-Label Pilot Study to Evaluate the Safety/Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of VTX2735 in Participants with Recurrent Pericarditis
2025-524784-20-00Recurrent Pericarditis
Zomagen Biosciences Limited
Cardiovascular Diseases
Belgium, France, Greece
27/02/2026
Phase IV
A multicentre randomized double-blind placebo-controlled 48-week superiority study to compare the efficacy and safety of rituximab versus placebo in rheumatoid arthritis-associated interstitial lung disease - the BELLRA trial.
2025-524872-51-00Rheumatoid arthritis-associated interstitial lung disease (…
Vaestra Goetalandsregionen
Immune System Diseases
Sweden
27/02/2026
Phase I
A study testing a new treatment called TK-6302 for the first time in people with advanced cancers that have a genetic marker called HLA-A02:01 and a tumour protein called PRAME.
2025-521603-46-00Advanced PRAME Positive Solid Tumors
T-Knife GmbH
Neoplasms
Germany
27/02/2026
Phase II
PirtobrUtinib as frontline Therapy for elderly unfit/frail patient with MAntle cell lymphoma: a phase II study of the Fondazione Italiana Linfomi (FIL)
2025-521666-10-01Mantle Cell Lymphoma
Fondazione Italiana Linfomi Ets
Hemic and Lymphatic Diseases
Italy
26/02/2026
Phase III
DIROXIMEL FUMARATE TO REDUCE PERIHAEMATOMAL OEDEMA IN INTRACEREBRAL HAEMORRHAGE: A DOUBLE BLIND RANDOMIZED CLINICAL TRIAL (DARLENE)
2025-522687-33-00Stroke
Centre Hospitalier Universitaire De Lille
Nervous System Diseases
France
26/02/2026
Phase II
STARS - Prospective, bayesian, randomized, controlled, open-label, parallel-group, phase II interventional study evaluating efficacy and safety of secukinumab versus standard of care in active severe Takayasu patients
2024-516215-24-00TAkayasu ARteritiS
Assistance Publique Hopitaux De Paris
Immune System Diseases
France
26/02/2026
Phase III
A Phase III, Randomised, Open-Label, Multicentre Study of Datopotamab Deruxtecan or Docetaxel in Previously Treated TROP2-positive Advanced or Metastatic Non-squamous Non-Small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung17)
2024-520101-39-00TROP2 NMR-positive advanced or metastatic non-squamous non-…
AstraZeneca AB
Neoplasms
Spain, Poland, Hungary, Italy, Germany, France, Belgium, Austria
26/02/2026
Phase I
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
2025-524334-26-01Endometrial cancer (EC), Advanced or metastatic breast canc…
Bristol-Myers Squibb Services Unlimited Company
Neoplasms
Denmark
26/02/2026
Phase I
Phase 1 First-in-Human Study of JNJ-95566692 in Participants with NHLs
2025-523297-16-00Non-Hodgkin Lymphoid Malignancies (NHLs)
Janssen Cilag International
Neoplasms
Belgium, France, Spain
26/02/2026
Phase II
A double-blind, randomized, placebo-controlled, two arm, phase II clinical trial in parallel groups to evaluate the efficacy and tolerability of a rectal treatment with budesonide suppositories compared to placebo suppositories for amelioration of acute radiation proctitis symptoms in male patients aged 18 years or older with prostate carcinoma
2024-519359-27-00Acute radiation proctitis symptoms in male patients aged 18…
Dr. Falk Pharma GmbH
Digestive System Diseases
Germany, Austria
26/02/2026
Phase II
A Phase 2, Multicenter, Randomized, Double-blind Study of Safety and Efficacy of EL219 (Turletricin) versus Liposomal Amphotericin B or Voriconazole for Early Antifungal Therapy of Invasive Mould Infections (TREAT-1)
2025-522835-32-00Suspected Invasive Mould Infection
Elion Therapeutics Inc.
Bacterial Infections and Mycoses
Belgium, France, Spain, Italy
26/02/2026
Phase I
The effect of losartan on cephalexin
2025-525059-23-00healthy volunteers
Varsinais-Suomen hyvinvointialue
Not possible to specify
Finland
26/02/2026
Phase II
In vivo biological standardization of Olea europaea allergen extracts.
2025-523866-26-00Allergies
Asac Pharmaceutical Inmunology S.A.
Diagnosis
Spain
25/02/2026
Phase III
ASPIRIN - Acetylsalicylic acid versus placebo in addition to a local non-steroidal anti-inflammatory drug in the treatment of thrombotic episodes in superficial venous malformations in children aged 6 to 17 years: a controlled randomised, double-blind, cross-over, multicenter trial
2024-517595-38-00Thrombotic episodes in superficial venous malformations in …
Centre Hospitalier Regional Universitaire De Tours
Cardiovascular Diseases
France
25/02/2026
Phase II
Effect of H2 inhalation therapy on early recurrence after atrial fibrillation ablation. Multicenter, open-label, randomized phase II controlled trial.
2024-520131-33-00atrial fibrillation
Centre Hospitalier Universitaire Grenoble Alpes
Cardiovascular Diseases
France
25/02/2026
Phase III
A Phase 2/3, Multicenter, Open-Label, Non-Randomized Study to Evaluate Diagnostic Performance of GEH300079 (68Ga) Injection Positron-Emission Tomography (PET)/Computed Tomography (CT) for Detection of Peritoneal Carcinomatosis (PC) in Patients with Colorectal, Gastric, Ovarian, or Pancreatic Cancers (PERISCOPE)
2024-519384-18-00Colorectal, Gastric, Ovarian or Pancreatic Cancer
GE Healthcare Limited
Diagnosis
Sweden, Netherlands
25/02/2026
Phase II
B7981118 - A Phase 2b Randomized, Double Blind, 12-Week Placebo Controlled Study With a 12-Week Double-Blind Extension Period to Evaluate the Efficacy, Safety and Tolerability of Ritlecitinib (PF 06651600) in Adult Participants with Chronic Spontaneous Urticaria
2025-522642-44-00CHRONIC SPONTANEOUS URTICARIA
Pfizer Inc.
Skin and Connective Tissue Diseases
Spain, Germany, Bulgaria, Poland
25/02/2026
Phase III
Long Covid (LC)-Revitalize - A Long Covid Repurposed Drug Study
2025-522611-42-00Long Covid
Dr. Douglas D. Fraser
Virus Diseases
Italy
25/02/2026
Phase III
Studying Treatments in patients receiving androgen deprivation therapy (ADT) for Metastatic Prostate Cancer: Evaluation of Drug and radiation Efficacy: A 2nd multi-arm multi-stage randomised controlled trial (STAMPEDE2)
2025-522145-21-00Metastatic hormone sensitive prostate cancer
University College London
Neoplasms
Ireland, Germany, Spain
25/02/2026
Phase III
An Open-Label Study of Donidalorsen in Pediatric Patients Age 2 to Less than 12 Years Old with Hereditary Angioedema [Donidalorsen Treatment in Children with Hereditary Angioedema]
2025-523499-22-00Hereditary Angioedema (HAE)
Ionis Pharmaceuticals Inc.
Genetic Phenomena
Italy, Spain, Poland
25/02/2026
Phase III
A Phase 3, multicenter, open-label extension study to evaluate the long-term safety, tolerability, and efficacy of subcutaneous sonelokimab in participants with psoriatic arthritis (PsA)
2025-522471-28-00psoriatic arthritis (PsA)
MoonLake Immunotherapeutics AG
Musculoskeletal Diseases
Estonia, Croatia, Slovakia, Lithuania, Romania, Hungary, Germany, France, Latvia, Poland, Portugal, Greece, Czechia, Bulgaria, Finland, Spain
25/02/2026
Phase II
Open-label, Uncontrolled, Multicenter Trial to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Children From 2 Years to Less Than 18 Years of Age with Immunoglobulin G4 related Disease (IgG4-RD)
2025-520988-41-00Immunoglobulin G4 related Disease (IgG4-RD)
Amgen Inc.
Immune System Diseases
Greece, Poland, Italy, Spain
25/02/2026
Phase I/II
A Phase Ib/II, multi-site, open-label, two-part trial to evaluate the efficacy, safety, pharmacokinetics, and recommended combination dose of BNT324 with BNT327 in participants with advanced lung cancer
2024-520238-31-01Advanced Lung Cancer
BioNTech SE
Neoplasms
Spain, France, Italy, Poland
24/02/2026
Phase I
A study of the safety, tolerability, pharmacokinetics and preliminary efficacy of TNV108 in healthy adults and patients with diabetic peripheral neuropathy
2025-524258-32-00Diabetic Peripheral Neuropathy (DPN)
Tenvie Therapeutics Inc.
Musculoskeletal and Neural Physiological Phenomena
Netherlands
24/02/2026
Phase II
A Phase 2 Double-blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of DT-101 in Adults with Major Depressive Disorder
2025-522784-15-00Major Depressive Disorder
Draig Therapeutics Limited
Mental Disorders
Czechia, Bulgaria, Poland
24/02/2026
Phase IV
A multi-center, open label, longitudinal, observational, 12-week study of Flexilev treatment with the dosing device OraFID and accompanying digital app in Parkinson patients.
2025-524296-23-01Parkinsons Disease
Navamedic AB
Nervous System Diseases
Sweden
24/02/2026
Phase III
J2A-MC-GZPW: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Orforglipron on the Incidence of Major Adverse Cardiovascular Events in Participants With Established Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease
2025-523123-22-00Atherosclerosis Cardiovascular Disease, Chronic Kidney Dise…
Eli Lilly & Co.
Cardiovascular Diseases
Germany, Czechia, Lithuania, Spain, Austria, France, Hungary, Greece, Estonia, Netherlands, Slovakia, Poland, Romania, Bulgaria, Italy, Belgium
24/02/2026
Phase I
A Pilot, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Tolerability, Safety, and Pharmacokinetics of a Single Intra-articular Injection of CNTX-0066 in Participants with Chronic, Moderate-to-Severe Osteoarthritis Knee Pain
2025-523737-26-00Osteoarthritis of the knee
Centrexion Therapeutics Corp.
Musculoskeletal Diseases
Denmark
24/02/2026
Phase II
KEYMAKER-U01 Substudy 01J: A Randomized Phase 2 Umbrella Study With Rolling Arms of Investigational Agents for First-line Treatment of Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations
2025-521939-36-00Participants with KRAS G12C-Mutant, Advanced or Metastatic …
Merck Sharp & Dohme LLC
Neoplasms
Italy, Poland, Spain, Finland, Netherlands, Greece
24/02/2026
Phase III
A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3, maintenance study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s disease
2025-521037-86-00Immune system diseases
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Spain, Czechia, Lithuania, Hungary, Greece, Bulgaria, Poland, Belgium, France, Germany, Norway, Austria, Netherlands, Italy, Slovakia
24/02/2026
Phase III
A multicenter, multinational, randomized, double-blind, placebo-controlled Phase 3, induction study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn’s Disease
2025-521036-11-00Immune system disseases
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Slovakia, Netherlands, Poland, Greece, Czechia, Italy, Bulgaria, Belgium, Germany, Lithuania, Austria, Spain, Hungary, Norway, France
24/02/2026
Phase I
A Phase 1 Study to Assess Radiation Biodistribution, Dosimetry, Pharmacokinetics and Safety of GEH300079 (68Ga) Injection and Determine the Optimal Injected Activity and Timing of PET/CT Imaging in Patients with Peritoneal Carcinomatosis of Colorectal, Gastric, Pancreatic or Ovarian Origin
2025-522541-21-00Peritoneal Carcinomatosis of Colorectal,Gastric, Pancreatic…
GE Healthcare Limited
Neoplasms
Sweden
24/02/2026
Phase IV
Effect of Romosozumab vs. Denosumab on Coronary Atherosclerotic Damage in Postmenopausal Osteoporotic Women: A Phase IV, Low-Risk, Pharmacological Intervention Study. ATRIO Study.
2025-522592-29-00Coronary atherosclerotic status in women with postmenopausa…
Ospedale Galeazzi S.p.A.
Musculoskeletal Diseases
Italy
23/02/2026
Phase II
J2R-MC-YAAD: A Phase 2, Double-blind, Placebo-Controlled Study to Evaluate LY3537021 for the Treatment of Chemotherapy-Induced Nausea and Vomiting in Adult Participants With Malignant Disease
2025-522204-24-00Neoplasms, Vomiting, Drug-Related Side Effects and Adverse …
Eli Lilly & Co.
Neoplasms
Romania, Spain, France, Italy
23/02/2026
Phase III
INCA000585-201 - A PHASE 2A, OPEN-LABEL, MULTI-CENTER STUDY OF TAFASITAMAB IN ADULT PARTICIPANTS WITH AUTOIMMUNE BLOOD CELL DISORDERS
2025-521286-27-00Immune-mediated thrombocytopenia, Autoimmune thrombocytopen…
Incyte Corp.
Hemic and Lymphatic Diseases
Netherlands, Italy, Spain, France
23/02/2026
Phase I/II
A Phase 1/2, Global, Open-Label, Extension Study to Evaluate the Long-Term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study
2022-502911-12-00Propionic Acidemia
Moderna Inc.
Nutritional and Metabolic Diseases
Spain, Netherlands, France
23/02/2026
Phase I
ADCX-020 for the treatment of patients with locally advanced or metastatic cancers
2025-523959-65-00Locally Advanced or Metastatic Solid Tumors
Adcytherix
Not possible to specify
Spain
23/02/2026
Phase II
Open-label safety and efficacy trial of chlorhexidine and/or metronidazole pre-treatment followed by FB301 in women with bacterial vaginosis (BV)
2025-524362-20-00Bacterial vaginosis
Freya Biosciences ApS
Bacterial Infections and Mycoses
Germany
23/02/2026
Phase I
Relative bioavailability and safety study of pasireotide after a single-dose subcutaneous administration in the arm or in the thigh compared to in the abdomen using a ServoPen in healthy subjects.
2025-521830-27-00Post-bariatric hypoglycaemia
Recordati AG
Hormonal diseases
Germany
23/02/2026
Phase II
Obinutuzumab Treatment in Frequently Relapsing and Rituximab-Dependent Idiopathic Nephrotic Syndrome in Adults: a fully academic, single-arm, open, prospective, intervention trial
2025-523306-33-00Idiopathic Nephrotic Syndrome
Istituto Di Ricerche Farmacologiche Mario Negri
Immune System Diseases
Italy
23/02/2026
Phase I/II
A Phase 1 Study of Fentanyl Vaccine
2025-524277-16-00Opioid induced respiratory depression
ARMR Sciences Inc.
Environment and Public Health
Netherlands
23/02/2026
Phase I
OV-PRIME-R (Oncolytic Virotherapy to enhance PReoperative IMmunotherapy Efficacy in patients with proficient mismatch repair (pMMR) Rectal cancer
2025-524375-23-00Rectal cancer with proficient mismatch repair (pMMR)
Region Hovedstaden
Neoplasms
Denmark
23/02/2026
Phase III
A seamless Phase 2/3 randomized, open-label study to investigate efficacy and safety of frexalimab versus tacrolimus in adult kidney transplant recipients
2025-521521-33-00Kidney transplant rejection
Sanofi-Aventis Recherche & Developpement
Immune System Diseases
Germany, Hungary, Italy, Belgium, Czechia, Finland, Spain, Austria, Sweden, France, Denmark, Netherlands
23/02/2026
Phase IV
CANIDIAP; CANagliflozin In DIAlysis Patients
2025-522742-46-00Chronic Kidney disease
Universitair Medisch Centrum Groningen
Not possible to specify
Netherlands
23/02/2026
Phase III
Multicenter, Safety Follow-up Study to Assess Safety of Prior Treatment with Romosozumab in Children and Adolescents with Osteogenesis Imperfecta
2023-503293-21-00Osteogenesis Imperfecta
Amgen Inc.
Skin and Connective Tissue Diseases
Germany, Hungary, Italy, Belgium, Austria, Slovakia, Spain
23/02/2026
Phase II
PRODIGE 113 (FFCD 2314) – REWENEC – 01 STUDY Randomized trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI with a hybrid synthetic control arm in second line treatment of metastatic neuroendocrine carcinoma of gastro-enteropancreatic or unknown origin. Phase II comparative randomized study – multicentric
2024-519922-19-00Neuroendocrine carcinoma of gastro-enteropancreatic or unkn…
Hospices Civils De Lyon
Neoplasms
France
22/02/2026
Phase III
Phase 3 Randomized, Double-blind, Placebo-controlled Studies Assessing Ziftomenib in Combination with Either Standard of Care Nonintensive (Venetoclax+Azacitidine) or Intensive (7+3) Therapy in Patients with Untreated NPM1 Mutated or KMT2A Rearranged Acute Myeloid Leukemia
2025-521314-25-00NPM1-m and KMT2A-r Acute Myeloid Leukemia
Kura Oncology Inc.
Neoplasms
Belgium, Spain, Italy, Czechia, Hungary, Poland, France, Portugal, Germany, Greece
20/02/2026
Phase II
Phase 2 study of iadademstat for the treatment of patients with essential thrombocythemia resistant/intolerant to hydroxyurea
2025-523864-19-00Essential Thrombocythemia
Oryzon Genomics S.A.
Hemic and Lymphatic Diseases
Spain
20/02/2026
Phase III
TRITON-PN: A Phase 3, Global, Randomized, Open-Label Study to Evaluate the Efficacy and Safety of Nucresiran in Patients with Hereditary Transthyretin-Mediated Amyloidosis with Polyneuropathy (hATTR-PN)
2025-522544-40-00Hereditary transthyretin-mediated amyloidosis with polyneur…
Alnylam Pharmaceuticals Inc.
Nervous System Diseases
France, Italy, Greece, Spain, Sweden, Ireland, Cyprus, Portugal, Germany
20/02/2026
Phase IV
Efficacy and tolerability of a simethicone-containing evacuating solution for colorectal cancer screening colonoscopy: a randomized parallel comparative trial. CLEAN+
2025-523748-11-00colorectal cancer early detection
Fundacio De Recerca Clinic Barcelona-Institut D’Investigacions Biomediques August Pi I Sunyer
Digestive System Diseases
Spain
20/02/2026
Phase I
Single-centre clinical trial investigating the safety and tolerability of increasing multiple doses of nebulised SS0331 in healthy participants
2025-523530-30-00Treatment and post exposure prevention of respiratory tract…
Softox Defense Solutions AS
Bacterial Infections and Mycoses
Ireland
20/02/2026
Phase I/II
A Multi-Center, Phase 1/2, Open-Label, Single and Multiple Ascending Dose Study of CRMA-1001 to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy in Adults with Chronic Hepatitis B
2025-523619-12-00Chronic Hepatitis B
Nchroma Bio Inc.
Virus Diseases
France
20/02/2026
Phase I/II
A Single-center, Prospective, Non-randomized, Open, Pilot Study Evaluating the Safety and Performance of the Extroducer® Infusion Catheter System for Peri/Intratumoral Gemcitabine Delivery in Patients with Unresectable Locally Advanced Pancreatic Cancer
2025-524733-11-00Unresectable Locally Advanced Pancreatic Cancer
Smartwise Sweden AB
Digestive System Diseases
Sweden
20/02/2026
Phase I
A study to test different doses of BI 3923948 alone and in combination with an anti-PD-1 antibody in people with different types of advanced cancer (solid tumors)
2025-521438-27-00advanced, unresectable and/or metastatic solid tumors
Boehringer Ingelheim International GmbH, Boehringer Ingelheim Espana S.A.
Neoplasms
Sweden, France, Spain, Germany
19/02/2026
Phase I/II
A phase 1/2a, first-in-human, open-label, dose-escalating study with a safety expansion cohort to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and preliminary anti-tumour activity of TAX2 in patients with relapsed/refractory advanced/metastatic solid tumours
2025-521164-36-00Patients with relapsed/refractory advanced/metastatic ovari…
Apmonia Therapeutics
Neoplasms
Belgium, France
19/02/2026
Phase I
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Deucravacitinib tablets 6 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with SOTYKTU (deucravacitinib) tablets 6 mg, Distributed by Bristol-Myers Squibb Company, Princeton, New Jersey 08543 USA, in healthy, adult, human subjects under fasting condition.
2025-523838-13-00plaque psoriasis
Sun Pharmaceutical Industries Limited
Immune System Diseases
Romania
19/02/2026
Phase I
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single-dose, crossover bioequivalence study comparing Deucravacitinib tablets 6 mg, Manufactured by Sun Pharmaceutical Industries Limited, India with SOTYKTU (deucravacitinib) tablets 6 mg, Distributed by Bristol-Myers Squibb Company, Princeton, New Jersey 08543 USA, in healthy, adult, human subjects under fed condition
2025-523839-18-00plaque psoriasis
Sun Pharmaceutical Industries Limited
Immune System Diseases
Romania
19/02/2026
Phase II
A phase II, multicentre, open label clinical trial evaluating the efficacy and safety of oral decitabine plus ivosidenib in adult patients with newly diagnosed acute myeloid leukemia older than 60 years old and/or who are ineligible for standard induction chemotherapy
2025-523238-17-00Acute myeloid leukemia
Fundacion PETHEMA
Neoplasms
Spain, Portugal
19/02/2026
Phase I/II
Phase 1/2, Open Label, Sequential Cohort Study of a Single Intracranial Dose of rAAVOlig001-ASPA Gene Therapy for Treatment of Children with Typical Canavan Disease
2024-519412-13-00Canavan Disease, Canavan disease
Myrtelle Inc.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
France
18/02/2026
Phase III
A Multicenter, 12-Month, Randomized, Double Blind, Placebo-Controlled Phase 3 Efficacy and Safety Study of Daily Oral LUM 201 in Naïve-to-Treatment, Prepubertal Children with Growth Hormone Deficiency (GHD)
2025-523820-26-00Growth Hormone Deficiency (GHD)
Lumos Pharma LLC
Hormonal diseases
Romania, France, Italy, Poland, Spain
18/02/2026
Phase II
Efficacy and safety of a combined therapy with Alpha-Lipoic Acid and Benfotiamine in the symptomatic treatment of diabetic sensorimotor polyneuropathy - a prospective, randomized, controlled, parallel group, double-blind, double-dummy 3-arm trial
2025-521985-82-00Diabetic sensorimotor polyneuropathy (DSPN)
Woerwag Pharma GmbH & Co. KG
Nutritional and Metabolic Diseases
Hungary
18/02/2026
Phase II
Master Protocol Full Title: A Master Protocol for an Exploratory, Phase 2a, Proof-of-Concept Platform Study to Evaluate the Safety, Tolerability, and Efficacy of Multiple Regimens in Participants With Myasthenia Gravis. ISA 1 Full Title: An ISA to Master Protocol ARGX-999-2-MG-2000 for an Exploratory, Phase 2a, Proof-of-Concept Study to Evaluate the Safety, Tolerability, and Efficacy of Empasiprubart IV as Add-On Therapy to Efgartigimod IV in Participants With AChR-Ab Seropositive Generalized Myasthenia Gravis With a Partial Clinical Response to Efgartigimod.
2025-522492-28-00AChR-Ab Seropositive Generalized Myasthenia Gravis, Myasthe…
Argenx
Immune System Diseases
Spain, Poland, Germany, Netherlands, Greece, Italy, Belgium
18/02/2026
Phase I
A bioequivalence study comparing Empagliflozin 25 mg film-coated tablets, VIANEX S.A., Greece versus Jardiance 25 mg film-coated tablets, Boehringer Ingelheim International GmbH, Germany, in healthy male and female volunteers under fasting conditions.
2025-524910-28-00none - healthy volunteers
Vianex S.A.
Cardiovascular Diseases
Czechia
18/02/2026
Phase III
Double blind, multicenter, randomized, controlled trial of dexmedetomidine vs placebo in premature neonates receiving invasive ventilation
2023-509247-27-00Neonatal respiratory distress. Pain and discomfort
Centre Hospitalier Intercommunal Creteil
Anesthesia and Analgesia
France
18/02/2026
Phase I
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants with Early Alzheimer’s Disease
2025-523515-11-00Early Alzheimer's Disease
Denali Therapeutics Inc.
Nervous System Diseases
Netherlands
18/02/2026
Phase I/II
A Phase 1b/2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Investigate A) the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Ascending Doses of IM-101 in Adult Participants with Generalized Myasthenia Gravis, and B) the Efficacy and Safety of Treatment of IM-101 in Adult Participants with Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
2025-522406-20-00Generalized Myasthenia Gravis and Ocular Myasthenia Gravis
Immunabs Inc.
Nervous System Diseases
Bulgaria, Poland, Spain, Italy
18/02/2026
Rows per page Showing 1401–1500 of 2500
Previous 13 14 15 16 17 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS). Derived from the EMA Clinical Trials Information System. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-europe?page=15

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →

About this register

This register is built from the EU Clinical Trials Information System (CTIS), run by the European Medicines Agency: the single register for every trial authorised under the EU Clinical Trials Regulation (536/2014). CTIS held 12,479 trial records at the last sync on 24 Sep 2026, 03:17 UTC; this register shows the 2,500 most recently authorised of them, a stated recency window rather than the full archive. The list can be downloaded as CSV or JSON.

How many clinical trials does CTIS hold?

CTIS held 12,479 trial records at the last sync. Of the 2,500 most recently authorised trials shown in this register, 743 are Phase III. Trials are counted by authorisation, not by recruitment status, which CTIS does not publish in the same form as ClinicalTrials.gov.

→

Browse trials by member state

Spain (1015) France (884) Germany (862) Italy (739) Poland (582) Netherlands (531) Belgium (431) Czechia (331) Denmark (323) Hungary (258) Greece (233) Romania (211) Austria (208) Sweden (204) Bulgaria (199)
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.